Jia Li

The paper identifies NECTIN4 as a subtype-dependent determinant of tumor state and antitumor immunity in bladder cancer, linking its expression to response to enfortumab vedotin and checkpoint inhibitors.

This study identifies tumor-myeloid crosstalk as a driver of cisplatin resistance in bladder cancer and proposes PARP14 inhibition as a therapeutic strategy.

The paper identifies cis-regulatory elements for targeted gene delivery to nociceptors using multi-omic profiling and develops a sequence-based model to design synthetic enhancers.

This paper introduces BSJ-5-63, a PROTAC that degrades CDK12, CDK7, and CDK9, inducing BRCAness and blocking AR signaling to enhance PARP inhibitor sensitivity in prostate cancer.

This study shows TET1 is essential for FOXA2-mediated chromatin remodeling in pancreatic beta-cell differentiation by rescuing differentiation defects and restoring PAX4 hypomethylation.